Q3 EPS Estimates for Haemonetics Lifted by Zacks Research

Haemonetics Co. (NYSE:HAE) – Investment analysts at Zacks Research raised their Q3 2026 earnings per share (EPS) estimates for Haemonetics in a research note issued to investors on Monday, February 17th. Zacks Research analyst R. Department now forecasts that the medical instruments supplier will post earnings of $1.33 per share for the quarter, up from their previous forecast of $1.31. The consensus estimate for Haemonetics’ current full-year earnings is $4.55 per share. Zacks Research also issued estimates for Haemonetics’ Q3 2027 earnings at $1.48 EPS.

Haemonetics (NYSE:HAE) last announced its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%.

HAE has been the subject of several other research reports. Raymond James reaffirmed a “strong-buy” rating and set a $115.00 price target (down previously from $120.00) on shares of Haemonetics in a research note on Friday, February 7th. Needham & Company LLC lowered their price target on Haemonetics from $112.00 to $108.00 and set a “buy” rating for the company in a report on Friday, February 7th. JMP Securities lowered their price target on Haemonetics from $125.00 to $100.00 and set a “market outperform” rating for the company in a report on Friday, February 7th. Barrington Research lowered their price target on Haemonetics from $108.00 to $95.00 and set an “outperform” rating for the company in a report on Friday, February 7th. Finally, Bank of America lowered Haemonetics from a “neutral” rating to an “underperform” rating and lowered their price target for the company from $95.00 to $68.00 in a report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $101.67.

Haemonetics Stock Down 0.3 %

Shares of NYSE:HAE opened at $63.88 on Thursday. Haemonetics has a 1 year low of $58.80 and a 1 year high of $97.97. The business has a 50 day simple moving average of $73.37 and a two-hundred day simple moving average of $76.85. The firm has a market capitalization of $3.21 billion, a PE ratio of 25.15, a price-to-earnings-growth ratio of 1.09 and a beta of 0.39. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55.

Institutional Trading of Haemonetics

Hedge funds have recently bought and sold shares of the stock. TD Waterhouse Canada Inc. purchased a new stake in shares of Haemonetics during the 4th quarter valued at $25,000. Covestor Ltd lifted its holdings in shares of Haemonetics by 146.8% during the 4th quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier’s stock valued at $58,000 after purchasing an additional 439 shares during the last quarter. Whittier Trust Co. purchased a new stake in shares of Haemonetics during the 4th quarter valued at $62,000. Nisa Investment Advisors LLC lifted its holdings in shares of Haemonetics by 124.2% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier’s stock valued at $92,000 after purchasing an additional 632 shares during the last quarter. Finally, Parkside Financial Bank & Trust lifted its holdings in shares of Haemonetics by 25.6% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier’s stock valued at $92,000 after purchasing an additional 240 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.